Background Metastatic thyroid cancers that are refractory to radioiodine (iodine-131) are
associated with a poor prognosis. In mouse models of thyroid cancer, selective mitogen-…

Compared with conventional, whole-organ, S-factor-based dosimetry, 3-dimensional (3D),
patient-specific dosimetry better accounts for radionuclide distribution and anatomic patient …

PET is potentially very useful for the accurate in vivo quantitation of time-varying biological
distributions of radiolabeled antibodies over severaJ days. The short haff-livesof most …

Context BRAF V600E mutant thyroid cancers are often refractory to radioiodine (RAI).
Objectives To investigate the utility and molecular underpinnings of enhancing lesional iodide …

Salivary gland side effects (SSEs) can be a source of significant morbidity in thyroid cancer
patients receiving radioactive iodine (RAI) for remnant ablation or therapy. However, the …

The objective of this work was to determine normal organ 131 I dosimetry in patients undergoing
radioiodide therapy for thyroid cancer by use of serial scanning with 124 I PET. Methods…

Radioiodine remnant ablation (RRA) is frequently used after a thyroidectomy for differentiated
thyroid carcinoma because it has been reported to reduce the number of local recurrences …

Background: Oncogenic activation of mitogen-activated protein kinase (MAPK) signaling is
associated with radioiodine refractory (RAIR) thyroid cancer. Preclinical models suggest that …

Absorbed doses in 90 Y radioimmunotherapy are usually estimated by extrapolating from 111
In imaging data. PET using 86 Y (β + 33%; half-life, 14.7 h) as a surrogate radiolabel could …

There has been recent and growing interest in applying Cerenkov radiation (CR) for biological
applications. Knowledge of the production efficiency and other characteristics of the CR …